Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.
Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P. Darshan MS, et al. Among authors: gjyrezi a. Cancer Res. 2011 Sep 15;71(18):6019-29. doi: 10.1158/0008-5472.CAN-11-1417. Epub 2011 Jul 28. Cancer Res. 2011. PMID: 21799031 Free PMC article.
Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY.
Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, Stewart J, Zaher A, Szatrowski TP, Ballman KV, Kita K, Tasaki S, Bai Y, Portella L, Kirby BJ, Saad F, Eisenberger MA, Nanus DM, Giannakakou P. Tagawa ST, et al. Among authors: gjyrezi a. Clin Cancer Res. 2019 Mar 15;25(6):1880-1888. doi: 10.1158/1078-0432.CCR-18-0320. Epub 2018 Oct 9. Clin Cancer Res. 2019. PMID: 30301829 Free PMC article. Clinical Trial.
Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer.
Galletti G, Zhang C, Gjyrezi A, Cleveland K, Zhang J, Powell S, Thakkar PV, Betel D, Shah MA, Giannakakou P. Galletti G, et al. Among authors: gjyrezi a. Clin Cancer Res. 2020 Jul 15;26(14):3771-3783. doi: 10.1158/1078-0432.CCR-19-3018. Epub 2020 Apr 22. Clin Cancer Res. 2020. PMID: 32321717 Free PMC article. Clinical Trial.
Clinical Significance of AR-V567es in Prostate Cancer-Response.
Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Giannakakou P. Tagawa ST, et al. Among authors: gjyrezi a. Clin Cancer Res. 2019 Oct 1;25(19):6010-6011. doi: 10.1158/1078-0432.CCR-19-1820. Clin Cancer Res. 2019. PMID: 31575715 No abstract available.
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuyse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart J, Zaher A, Szatrowski T, Zhou W, Gjyrezi A, Tasaki S, Portella L, Bai Y, Lannin TB, Suri S, Gruber CN, Pratt ED, Kirby BJ, Eisenberger MA, Nanus DM, Saad F, Giannakakou P; TAXYNERGY Investigators. Antonarakis ES, et al. Among authors: gjyrezi a. J Clin Oncol. 2017 Oct 1;35(28):3181-3188. doi: 10.1200/JCO.2017.72.4138. Epub 2017 Jun 20. J Clin Oncol. 2017. PMID: 28632486 Free PMC article. Clinical Trial.
13 results